All In Biotech

Drug Trial Radar · NCT04196101

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Jan 22, 2020

Primary completion

Jan 4, 2022

Study completion Jan 4, 2022

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Dec 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • EDP-938Drug

    Four tablets daily for 5 days

  • PlaceboDrug

    Four tablets daily for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Symptom Score (TSS) Area Under the Curve (AUC)Time frame: Day 1 through Day 14

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Cahaba Research Inc. - Birmingham

    Pelham, Alabama

  • Saint Joseph's Clinical Research

    Anaheim, California

  • Torrance Clinical Research Institute

    Lomita, California

  • Miami Clinical Research - ClinEdge - PPDS

    Miami, Florida

  • Pioneer Clinical Research LLC

    Bellevue, Nebraska

  • Meridian Clinical Research

    Norfolk, Nebraska

  • Clinical Research of South Nevada

    Las Vegas, Nevada

  • Carolina Research Center

    Shelby, North Carolina

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • Progressive Medicine of the Triad, LLC

    Winston-Salem, North Carolina

  • FMC Science

    Lampasas, Texas

  • Instituto Medico Platense

    Buenos Aires, Argentina

  • Multiprofile Hospital for Active Treatment Puls

    Blagoevgrad, Bulgaria

  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD

    Haskovo, Bulgaria

  • Medical Center Zdrave-1 OOD

    Kozloduy, Bulgaria

  • Medical Center Tara OOD

    Veliko Tarnovo, Bulgaria

  • Diagnostic and Consulting Center Aleksandrovska EOOD

    Sofia, Sofia-Grad, Bulgaria

  • Medical Center Hera

    Sofia, Sofia-Grad, Bulgaria

  • Lakeland Clinical Trials - Waikato

    Hamilton, New Zealand

  • Lakeland Clinical Trials

    Rotorua, New Zealand

  • Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota

    Ostróda, Poland

  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o

    Tarnów, Lesser Poland Voivodeship, Poland

  • Clinical Projects Research SA pty Ltd

    Worcester, Western Cape, South Africa

  • City Outpatient Clinic #9

    Kyiv, Ukraine

  • Medical Center of LLC Preventclinic

    Kyiv, Ukraine

  • Limited Liability Company Medical Center Consilium Medical

    Kyiv, Ukraine

  • Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

  • Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council

    Poltava, Poltava Oblast, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.